A ≥48-month interim analysis from Xenon’s ongoing seven-year X-TOLE open-label extension will be featured at AES 2025, focusing on long-term safety and efficacy of azetukalner in adults with focal epilepsy and, notably, on the ability to attain and regain extended seizure-freedom epochs with prolonged use. The company will also present analyses characterizing patterns of seizure-free periods over time, positioning durability—rather than only responder rates—as a central outcome.
The core news is a coordinated data drop across seven posters: two readouts from the X-TOLE extension examining multi-year exposure to azetukalner, a selective KV7 channel opener, and five studies that broaden the context around epilepsy care and Xenon’s pipeline. These include patient-reported outcomes on depression in focal seizures, a retrospective claims analysis on how depression affects treatment patterns and outcomes in newly diagnosed epilepsy, models quantifying economic and humanistic burden among patients with moderate-to-severe depressive symptoms, and a thematic analysis on the clinical and patient burden of anti-seizure medication titration. Rounding out the slate is preclinical work from Xenon’s NaV1.1 program in Dravet syndrome, reporting seizure suppression, SUDEP prevention, and increased long-term potentiation in mouse models.
Strategically, the emphasis on seizure-freedom epochs and long-horizon safety reads as pre-NDA groundwork for azetukalner’s Phase 3 program in focal seizures and mood disorders. In a focal epilepsy market increasingly defined by high responder rates but operationally complex titration and combination regimens, durability of seizure freedom and ease of use are becoming differentiators for both regulators and prescribers. The titration-burden analysis highlights a practical edge if azetukalner can deliver meaningful control without extended step-up schedules that complicate adherence, increase site workload, and lengthen trials. The depression-focused real-world and outcomes research also signals a broader indication strategy: building a health-economic and quality-of-life dossier that connects epilepsy control with psychiatric comorbidities while Xenon advances azetukalner in MDD and bipolar depression.
For sites and CROs, the long-term OLE data underscore operational realities that are likely to carry into Phase 3 and beyond: sustained eDiary compliance, standardized definitions of seizure-freedom epochs and relapse, and retention tactics that preserve data integrity over years. If durability metrics become prominent secondary endpoints, study durations may extend, reshaping visit schedules, adjudication processes, and rescue pathways. Vendors supporting ePRO, seizure analytics, and decentralized follow-up will see increased demand as sponsors try to capture fine-grained epoch data without overburdening coordinators. For payers and health systems, the depression and burden studies pre-wire value narratives that go beyond seizure counts—critical in a class where incremental responder-rate gains are expensive and often clinically ambiguous. Regulators will expect a robust statistical plan to analyze epoch-based outcomes prospectively and to contextualize OLE findings against selection bias inherent in long, open-label cohorts.
The next signals to watch are the timing and design of Xenon’s upcoming Phase 3 readouts in focal epilepsy, including whether seizure-freedom epochs are prospectively powered and how long-term durability is addressed in statistical hierarchy. Multi-year safety, drug–drug interaction profile, and titration simplicity relative to incumbents will determine both regulatory traction and site uptake. In Dravet syndrome, NaV1.1 potentiation is strategically adjacent but will require careful translational endpoints, early pediatric regulatory dialogue, and biomarker strategy to move from preclinical SUDEP prevention to clinically meaningful outcomes. Overall, Xenon is attempting to reset the evidence conversation toward durability, comorbidity burden, and operational simplicity—levers that could resonate with sites navigating staffing constraints and with payers scrutinizing cost for marginal efficacy gains.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
